Recently diagnosed with HIV? Click here

GB Virus C, HIV and HCV

Clinical trial • Reported • 17 February 2010
This trial is concluded. This means the trial has been completed. The results of the trial are summarised in the 'results' section of this page. You cannot enrol in this trial.

About this trial

It has been reported that GB virusA small infective organism which is incapable of reproducing outside a host cell. C infection (GBV-C or formerly known as hepatitis G) leads to improved outcomes for people with HIV . However, GBV-C has no effect on the course of liverA large organ, located in the upper right abdomen, which assists in digestion by metabolising carbohydrates, fats and proteins, stores vitamins and minerals, produces amino acids, bile and cholesterol, and removes toxins from the blood. disease in people with hepatitis C virus (HCVHepatitis C virus.) . So, the aim of the study  is to determine the influence of GBV-C infection on liver disease in patients with both HCV and HIV.

Official title:Associations, Outcomes and Genomics of GB Virus C, Hepatitis C Virus and Human Immunodeficiency Virus Infection
What is this trial studying?Other – antiretrovirals
Start date:2004

This may be the proposed or expected start date for trials which have not yet started.

Links to further information:
Tags:hepatitis C, hepatotoxicity, liver disorders, symptoms, illnesses and opportunistic infections

Who can enrol in this trial?

You may be eligible to participate in this trial if you meet the following criteria:

  • At least years old

This is a summary of key inclusion and exclusion criteria for this trial. There may be other criteria which may exclude some people from participation in this trial. Some laboratory tests may also be required. Consult your doctor, or view the trial protocol or informed consent documentation to see the full range of exclusion and inclusion criteria.

Results:

57 of 158 (36%) patients had GBV-C RNA and 94 (59%) had evidence of exposure to GBV-C . 34 (21%) patients had features of cirrhosis.

Active GBV-C was significantly associated with a reduction in cirrhosis.

CONCLUSIONS: In these HCVHepatitis C virus./HIV-coinfected people, GBV-C was associated with a significant reduction in the severity of HCV-related liverA large organ, located in the upper right abdomen, which assists in digestion by metabolising carbohydrates, fats and proteins, stores vitamins and minerals, produces amino acids, bile and cholesterol, and removes toxins from the blood. disease.

For full results see PubMed link above.

 

Disclaimer

While NAPWA has taken every care to compile the information on this page and to keep it up-to-date, we cannot guarantee its correctness and completeness.

  • Before making the decision to participate in any clinical research, read our background information.
  • Email NAPWA if you have any questions or comments about this trial
Text size: font smallerfont normalfont larger print-friendly version of this pagePDF version of this pageemail this page to a friend

This Clinical trial was first published on 17 February 2010 — more than one year ago.

While the content of this clinical trial was checked for accuracy at the time of publication, NAPWA recommends checking to determine whether the information is the most up-to-date available, especially when making decisions which may affect your health.

This article may contain medical information. NAPWA makes every reasonable effort to ensure the information on this website is accurate, reliable and up-to-date, including obtaining technical reviews by medically-qualified reviewers, however the authors of information on this website are not qualified to give medical advice, except where explicitly stated.

The content of this website is intended to support, not replace, the relationship between people living with HIV/AIDS and their medical advisers, and is not intended as a substitute for medical advice.

HIV Clinical Trials update

Recently updated entries from the NAPWA Clinical Trials database.

more